FDA Drug recall D-1436-2014
Apri (desogestrel and ethinyl estradiol tablets USP), 0.15 mg/0.03 mg, 6 Cyclic dispensers X 28 tablets, Rx only, Teva Pharmaceuticals, Sel…
- FDA Drug
- Class III
- terminated
- Published 2014-07-23
On 2014-07-23 the FDA classified a Class III recall of Apri (desogestrel and ethinyl estradiol tablets USP), 0.15 mg/0.03 mg, 6 Cyclic dispensers X 28 tablets, Rx only, Teva Pharmaceuticals, Sel… by Teva Pharmaceuticals Usa, citing failed Impurities/Degradation Specifications: out of specification impurity test results.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1436-2014 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2014-06-17 |
| Published | 2014-07-23 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Teva Pharmaceuticals Usa |
| Distribution | US |
Product
Apri (desogestrel and ethinyl estradiol tablets USP), 0.15 mg/0.03 mg, 6 Cyclic dispensers X 28 tablets, Rx only, Teva Pharmaceuticals, Sellersville, PA. NDC 0555-9043-58
Reason
Failed Impurities/Degradation Specifications: out of specification impurity test results.
Identifiers
| ndc | 0555-9043-79 |
|---|---|
| ndc | 0555-9043-58 |
| code_info | Lot 3805324A Exp. 11/14 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1436-2014%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.